Skip to content
10-Q

Quarterly Report

Nexvet Biopharma plc

0001564590-17-010408

← back to feed
Filed
May 11, 2017 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2017 · Apr 30, 2017 11.92M sh
Cash And Equivalents Q3 2017 · Mar 31, 2017 $14.52M
Cash And Equivalents Q3 2017 · Jun 30, 2016 $31.48M
Cash And Equivalents Q3 2017 · Mar 31, 2016 $37.16M
Cash And Equivalents Q3 2017 · Jun 30, 2015 $52.03M
Stockholders Equity Q3 2017 · Mar 31, 2017 $20.92M
Stockholders Equity Q3 2017 · Jun 30, 2016 $35.14M
Stockholders Equity Q3 2017 · Jun 30, 2015 $53.58M
Current Liabilities Q3 2017 · Mar 31, 2017 $3.56M
Current Liabilities Q3 2017 · Jun 30, 2016 $5.05M
Total Liabilities Q3 2017 · Mar 31, 2017 $3.83M
Total Liabilities Q3 2017 · Jun 30, 2016 $5.19M
Current Assets Q3 2017 · Mar 31, 2017 $18.96M
Current Assets Q3 2017 · Jun 30, 2016 $34.96M
Total Assets Q3 2017 · Mar 31, 2017 $24.75M
Total Assets Q3 2017 · Jun 30, 2016 $40.32M
Sga Expense Q3 2017 · Mar 31, 2017 $1.61M
Sga Expense Q3 2017 · Mar 31, 2017 $5.25M
Sga Expense Q3 2017 · Mar 31, 2016 $1.68M
Sga Expense Q3 2017 · Mar 31, 2016 $5.33M
Rd Expense Q3 2017 · Mar 31, 2017 $5.58M
Rd Expense Q3 2017 · Mar 31, 2017 $12.8M
Rd Expense Q3 2017 · Mar 31, 2016 $4.26M
Rd Expense Q3 2017 · Mar 31, 2016 $11.78M
Net Income Q3 2017 · Mar 31, 2017 −$6.02M
Net Income Q3 2017 · Mar 31, 2017 −$16.53M
Net Income Q3 2017 · Jun 30, 2016 −$19.37M
Net Income Q3 2017 · Mar 31, 2016 −$5.75M
Net Income Q3 2017 · Mar 31, 2016 −$15.4M
Operating Income Q3 2017 · Mar 31, 2017 −$7.19M
Operating Income Q3 2017 · Mar 31, 2017 −$18.05M
Operating Income Q3 2017 · Mar 31, 2016 −$5.94M
Operating Income Q3 2017 · Mar 31, 2016 −$17.1M
Capex restated Q3 2017 · Sep 30, 2015 $1.98M